Search Results 61-70 of 16909 for Hodgkin disease
Chronic myelogenous leukemia; Congenital metabolic disorder; Hemoglobinopathies; Hodgkin lymphoma (Hodgkin disease) ... Non-Hodgkin's lymphoma; Plasma cell ...
Giving doxorubicin hydrochloride, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma ...
These conditions include such cancers as multiple myeloma, Hodgkin lymphoma ... The disease course and treatment varies widely depending on the type of ...
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma ... disease, and previous treatments or ...
Participation eligibility · Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin ...
... Hodgkin lymphoma. Combinations of biological substances in brentuximab ... Participant eligibility includes age, gender, type and stage of disease, and previous ...
Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma. Participation eligibility. Participant ...
... Hodgkin lymphoma. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...
— A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates.
Lymphoma Epidemiology of Outcomes (LEO) Cohort. The goal of the LEO study is to build and maintain a large and diverse cohort of non-Hodgkin lymphoma (NHL) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.